Electrome Investor Update on Platform Progress

Electrome Corporation today summarized recent platform progress for investors and partners. The PAINKILLER consumer surface, the provider program, the retailer program, the affiliate network, and the research collaborations are each operating at the cadence the company committed to at launch. The data room and the investor portal contain the supporting materials.

Summary

The platform's underlying device supply, regulatory posture, and clinical evidence base remain unchanged from prior disclosures. Operational milestones across the program lines are on plan. Specific partner names and counts are disclosed only when partners authorize disclosure.

Forward looking statements

This release includes forward looking statements regarding platform progress. Actual results may differ materially.

About the platform

The Electrome platform is the software backbone that connects the FDA cleared pulsed shortwave therapy device behind PAINKILLER to the patient, the clinician, the retailer, the affiliate, and the research partner. The platform captures device telemetry, brief patient reported outcomes, and clinical context where a clinician is in the loop, and it presents that information through the surface that fits each role in the network. The cumulative effect over time is a coherent product experience for the patient and a coordinated operating layer for the partner network.

About the investor channel

The investor portal and the data room are the primary surfaces through which qualified investors access the company's filings, summary documents, and operating updates. Access is granted through a managed verification process. The materials presented in those surfaces are intended for accredited investors and qualified institutional buyers and are not a public solicitation of any security.

About Electrome Corporation

Electrome Corporation operates the bioelectric medicine platform behind PAINKILLER and a portfolio of clinical, research, and commercial programs. The company's stated focus is on building the infrastructure layer of bioelectric medicine in a way that is rigorous, transparent, and aligned with the regulatory boundaries of the cleared device.